AI Drug R&D Startup XtalPi Announces Over 300 Million Series C Investment Led by SoftBank Vision Fund, PICC Capital, and Morningside

CAMBRIDGE, Mass. and SHENZHEN, China, Sept. 28, 2020 /PRNewswire/ —¬†XtalPi, an Artificial Intelligence (AI) drug discovery and development technology company, today announces an oversubscribed Series C funding of $318.8 million co-led by SoftBank Vision Fund 2i, PICC Capital, and Morningside. The new round of financing is joined by over a dozen global investment companies in banking and technology, with follow-on investments from existing investors Tencent, Sequoia China, China Life, and SIG.

XtalPi Logo (PRNewsfoto/XtalPi Inc.)
XtalPi Logo (PRNewsfoto/XtalPi Inc.)

With the new round of funding, XtalPi will bring the power of quantum physics, AI, and almost limitless cloud resources to propel research scientists towards drug candidates with tailored pharmaceutical profiles. Its platform takes the unique approach of combining physics-based and data-driven models to comprehensively address all drug properties relevant to progression into clinical studies. By integrating the predictions of its virtual R&D platform with real-world data from modern laboratories, XtalPi

Read More